Inhibition of P-glycoprotein and Glutathione S-transferase-pi mediated resistance by fluoxetine in MCF-7/ADM cells

Biomedicine and Pharmacotherapy

Volumn 67, Issue 8, 2013, Pages 757-762

  Zhang, Ye ^a   Zhou, Ting ^a   Duan, Jingjing ^a   Xiao, Zhijun ^a   Li, Guihua ^a   Xu, Feng ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Fluoxetine; GST ; Multidrug resistance; P gp

Indexed keywords

DOXORUBICIN; FLUOXETINE; GLUTATHIONE TRANSFERASE P1; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CELL VIABILITY; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; GENE EXPRESSION; HUMAN; HUMAN CELL; MONOTHERAPY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

FLUOXETINE; GST-Π; MULTIDRUG RESISTANCE; P-GP;

ANTINEOPLASTIC AGENTS; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FLUOXETINE; GLUTATHIONE S-TRANSFERASE PI; HUMANS; MCF-7 CELLS; P-GLYCOPROTEIN; PACLITAXEL;

EID: 84887618455     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2013.04.012     Document Type: Article

References (26)

1. Baguley B.C. Multiple drug resistance mechanisms in cancer. Mol Biotechnol 2010, 46(3):308-316.
2. Stavrovskaya A.A. Cellular mechanisms of multidrug resistance of tumor cells. Biochemistry (Mosc) 2000, 65(1):95-106.
3. O'Connor R. A review of mechanisms of circumvention and modulation of chemotherapeutic drug resistance. Curr Cancer Drug Targets 2009, 9(3):273-280.
4. Leonard G.D., Fojo T., Bates S.E. The role of ABC transporters in clinical practice. Oncologist 2003, 8(5):411-424.
5. Sato K., Tsuchida S., Tamai K. Anti-cancer drug resistance and glutathione S-transferases. Gan To Kagaku Ryoho 1989, 16:592-598.
6. Batist G., Tulpule A., Sinha B.K., Katki A.G., Myers C.E., Cowan K.H. Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. J Biol Chem 1986, 261:15544-15549.
7. Massie M.J., Holland J.C. Depression and the cancer patient. J Clin Psychiatry 1990, 51:12-17.
8. Cheer S.M., Goa K.L. Fluoxetine: a review of its therapeatic patential in the treatment of depression with physical illness. Drugs 2001, 61(1):81-110.
9. Navari R.M., Razavi D., Allilaire J.F., Smith M., Salimpour A., Verra M., et al. The effect of fluoxetine on anxiety and depression symptoms in cancer patients. Acta Psychiatr Scand 1996, 94(3):205.
10. Navari R.M., Brenner M.C., Wilson M.N. Treatment of depressive symptoms in patients with early stage breast cancer undergoing adjuvant therapy. Breast Cancer Res Treat 2008, 112:197-201.
11. Peer D., Dekel Y., Melikhov D., Margalit R. Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models. Cancer Res 2004, 64:7562-7569.
12. Li X., Li J.P., Yuan H.Y., Gao X., Qu X.J., Xu W.F., et al. Recent advances in P-glycoprotein-mediated multidrug resistance reversal mechanisms. Methods Find Exp Clin Pharmacol 2007, 29(9):607-617.
13. Leonard G.D., Polgar O., Bates S.E. ABC transporters and inhibitors: new targets, new agents. Curr Opin Invest Drugs 2002, 3(11):1652-1659.
14. Cen J., Qi Y. HZ08, a great regulator to reverse multidrug resistance via cycle arrest and apoptosis sensitization in MCF-7/ADM. Eur J Pharmacol 2010, 647(1-3):21-30.
15. Kars M.D., Işeri O.D., Gunduz U., Molnar J. Reversal of multidrug resistance by synthetic and natural compounds in drug-resistant MCF-7 cell lines. Chemotherapy 2008, 54(3):194-200.
16. Pires M.M., Emmert D., Hrycyna C.A., Chmielewski J. Inhibition of P-glycoprotein-mediated paclitaxel resistance by reversibly linked quinine homodimers. Mol Pharmacol 2009, 75(1):92-100.
17. Steingart A.B., Cotterchio: M. Do antidepressants cause, promote, or inhibit cancers?. J Clin Epidemiol 1995, 48(11):1407-1412.
18. Freire-Garabal M., Núñez M.J., Pereiro D., Riveiro P., Losada C., Fernández-Rial J.C., et al. Effects of fluoxetine on the development of lung metastases induced by operative stress in rats. Life Sci 1998, 63(2):31-38.
19. Peer D., Margalit R. Fluoxetine and reversal of multidrug resistance. Cancer Lett 2006, 237:180-187.
20. Argov M., Kashi R., Peer D., Margalit R. Treatment of resistant human colon cancer xenograftsby a fluoxetine-doxorubicin combination enhances therapeutic responses comparable to an aggressive bevacizumab regimen. Cancer Lett 2009, 274:118-125.
21. Ong J.C., Sun F., Chan E. Development of stealth liposome co-encapsulating doxorubicin and fluoxetine. J Liposome Res 2011, 21(4):261-271.
22. Smith A.J., Van Helv oort A., Van Meer G., et al. MDR3 P-glycoprotein, a phosphatidyl-choline translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. J Biol Chem 2000, 275(31):23530-23539.
23. Kuo M.T. Roles of multidrug resistance genes in breast cancer chemoresistance. Adv Exp Med Biol 2007, 608:23-30.
24. Weiss J., Dormann S.M., Martin-Facklam M., Kerpen C.J., Ketabi-Kiyanvash N., Haefeli W.E. Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther 2003, 305(1):197-204.
25. Caraci F., Crupi R., Drago F., Spina E. Metabolic drug interactions between antidepressants and anticancer drugs: focus on selective serotonin reuptake inhibitors and hypericum extract. Curr Drug Metab 2011, 12(6):570-577.
26. Barbey J.T., Roose S.P. SSRI safety in overdose. J Clin Psychiatry 1998, 59:42-48.